about
Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paperEffects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studiesEffects of Levosimendan on Cellular Metabolic Alterations in Patients with Septic Shock: A Randomized Controlled Pilot Study.Comparison of an automatic analysis and a manual analysis of conjunctival microcirculation in a sheep model of haemorrhagic shock.Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics.Clinical effects of laparotomy with perioperative continuous peritoneal lavage and postoperative hemofiltration in patients with severe acute pancreatitis.Ventriculoarterial decoupling in human septic shock.An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial.Beta-blocker use in severe sepsis and septic shock: a systematic review.Extracorporeal carbon dioxide removal (ECCO2R) in patients with acute respiratory failure.Severe community onset healthcare-associated Clostridium difficile infection complicated by carbapenemase producing Klebsiella pneumoniae bloodstream infection.Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental studyEffects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shockPrevention of cardiac surgery-associated acute kidney injury.Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial."Terlipressin in the treatment of septic shock: the earlier the better"?Role of vasopressinergic V1 receptor agonists in the treatment of perioperative catecholamine-refractory arterial hypotension.Renal effects of levosimendan: a consensus report.Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock.Randomized evidence for reduction of perioperative mortality.Reducing mortality in acute kidney injury patients: systematic review and international web-based survey.Effect of Conservative vs Conventional Oxygen Therapy on Mortality Among Patients in an Intensive Care Unit: The Oxygen-ICU Randomized Clinical Trial.Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.Venovenous extracorporeal membrane oxygenation for acute respiratory failure : A clinical review from an international group of experts.Hemodynamic coherence in sepsis.Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study.Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study.Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.Esmolol in septic shock: old pathophysiological concepts, an old drug, perhaps a new hemodynamic strategy in the right patient.Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis.Effects of balanced crystalloid vs. 0.9% saline-based vs. balanced 6% tetrastarch infusion on renal function and tubular integrity in ovine endotoxemic shock.Rescue treatment for noninvasive ventilation failure due to interface intolerance with remifentanil analgosedation: a pilot study.Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock.Not everything labeled "low-dose" vasopressin is a low dose.Renal effects of saline-based 10% pentastarch versus 6% tetrastarch infusion in ovine endotoxemic shock.Reducing the risk of major elective non-cardiac surgery: is there a role for levosimendan in the preoperative optimization of cardiac function?Effects of two different dosing regimens of terlipressin on organ functions in ovine endotoxemia.Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia.Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial.
P50
Q26738701-7DE83D57-40FA-4FE2-93EE-DFEEC3AD7190Q28249459-B4D9EF73-8B6D-4030-B312-4681CB946E1CQ30490959-3C964800-E92E-4F55-BE77-A9CBD482587FQ30829110-ACF664D9-1A32-4CDC-9E6F-5ABDB14A0EC4Q31157664-35BE642C-6CDC-46A1-99E7-AAA381CAF5A6Q33210353-F0219BF2-0F20-43B6-8C6B-229A968C8A55Q33578578-97D9C95E-705D-400A-B029-2235CBDEEC31Q33751885-773EA359-2B03-4F5B-8059-22CB8032F342Q33770902-9A013A82-56D0-42F1-8464-EDAA60F77E3AQ34482766-504FDD20-E115-48C3-B7B3-DEDF9422072BQ34550204-A6318BB3-55B0-4F10-A80C-16451839DBC0Q35236296-CF1AA6A3-598E-4F51-B3DA-90009A5CA56DQ35561294-5DB88215-BD67-4F15-9B5D-07B95E35FF2AQ35908131-7D242433-E379-4899-93D0-9C40ECFB8854Q37098852-123CF21E-6FFC-45F2-B977-BF492A9D76A8Q37105993-5E5B35C0-FEA0-40AB-9D50-2DF89F0F2779Q37236194-B9D2800D-0BAA-449B-AC85-C8849A610907Q37236212-FE455B84-89D6-4D16-B4E5-99BA142A1B8CQ37314324-CEE17B07-EEC2-47C3-924C-2F3EF73FD835Q37593091-C09A4E36-1B89-4170-AEDD-C27A11335149Q38021061-7194C753-230F-49DE-B0FD-CF19B641D2BDQ38150584-9DD3FC7E-44CA-436B-A3C7-68B1AD4C11DAQ38386372-C9C646FF-06B4-4B4C-B7A2-443F0EDDEB74Q38443276-4EF9386A-BCB2-4C63-AD67-28065139D910Q38785987-B64E24AC-0685-4F62-BC53-2F3D4E233FF6Q39033282-FC44196E-0863-4935-9CFA-E59FE6D56290Q39205985-8C33978B-8704-46D0-82EB-43F8A0C02323Q39833414-AB9D7EE8-72BF-4779-84C5-008B5725B732Q40802659-4A194FE1-5369-4796-81B8-7B03FCE367DDQ42344281-A3006D51-61B7-4634-8F61-FD7EC8F92CA0Q42672323-B4757B3D-49D7-4FFD-9EAD-30DC8B65ED9CQ42685935-0D50BFB8-16F0-4AC8-B6A8-588283724BA6Q42905120-4633F757-AFA8-4359-A15B-0EA22746C17CQ42958949-C4E096A7-FBC4-4D2C-814A-5DF4615AC4CAQ43079391-5232E1ED-4C8E-44B9-AE02-51D8D4F5EB1AQ43127104-31007F59-51A7-4AEE-9CC8-862A93276BADQ43267972-E9BC9CDF-E7D3-488C-890E-AA0414B69819Q43601541-5B6AD593-9269-4CF7-84B2-DF79F985EC6CQ43830886-D9B8A263-0FCA-4241-A3F2-61836ABC72D8Q44030727-3D821512-5FBF-4CB4-8A25-265D68FFB1CF
P50
description
onderzoeker
@nl
shoe designer
@en
name
Andrea Morelli
@ast
Andrea Morelli
@en
Andrea Morelli
@es
Andrea Morelli
@nl
type
label
Andrea Morelli
@ast
Andrea Morelli
@en
Andrea Morelli
@es
Andrea Morelli
@nl
prefLabel
Andrea Morelli
@ast
Andrea Morelli
@en
Andrea Morelli
@es
Andrea Morelli
@nl
P106
P1153
7102697349
P31
P496
0000-0001-6065-1006